HighTide Therapeutics (HKSE:02511) Net Cash per Share : HK$1.37 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is HighTide Therapeutics Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). HighTide Therapeutics's Net Cash per Share for the quarter that ended in Dec. 2023 was HK$1.37.

The historical rank and industry rank for HighTide Therapeutics's Net Cash per Share or its related term are showing as below:

HKSE:02511' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 4.55 Med: 9.46 Max: 9.46
Current: 4.55

During the past 3 years, the highest Price-to-Net-Cash Ratio of HighTide Therapeutics was 9.46. The lowest was 4.55. And the median was 9.46.

HKSE:02511's Price-to-Net-Cash is ranked worse than
55.11% of 871 companies
in the Biotechnology industry
Industry Median: 4.06 vs HKSE:02511: 4.55

HighTide Therapeutics Net Cash per Share Historical Data

The historical data trend for HighTide Therapeutics's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HighTide Therapeutics Net Cash per Share Chart

HighTide Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Net Cash per Share

-0.68

-1.05

1.37

HighTide Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
Net Cash per Share	-0.68	-	-1.05	-2.24	1.37

Competitive Comparison of HighTide Therapeutics's Net Cash per Share

For the Biotechnology subindustry, HighTide Therapeutics's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HighTide Therapeutics's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HighTide Therapeutics's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where HighTide Therapeutics's Price-to-Net-Cash falls into.

HighTide Therapeutics Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

HighTide Therapeutics's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as

	Net Cash per Share (A: Dec. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(804.694	-	100.914	-	0)	/	514.771
=	1.37

HighTide Therapeutics's Net Cash per Share for the quarter that ended in Dec. 2023 is calculated as

	Net Cash per Share (Q: Dec. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(804.694	-	100.914	-	0)	/	514.771
=	1.37

HighTide Therapeutics (HKSE:02511) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.

HighTide Therapeutics Net Cash per Share Related Terms

Thank you for viewing the detailed overview of HighTide Therapeutics's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

HighTide Therapeutics (HKSE:02511) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HighTide Therapeutics Inc (HKSE:02511) » Definitions » Net Cash per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ganli Second Road, 18B-102, Zhonghaixin Innovation Industry City, Jihua Neighborhood, Longgang District, Guangdong, Shenzhen, CHN, 518112

Website

https://www.hightidetx.com

HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The company has developed a product pipeline of five product candidates in-house, covering nine indications in metabolic and digestive diseases among which, five are at clinical-stage. The Core Product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases.

HighTide Therapeutics (HKSE:02511) Headlines

No Headlines